SYSTEMATIC REVIEW
Published on 13 Mar 2023
Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment
doi 10.3389/frhs.2023.1034256
- 2,027 views